Aldeyra Therapeutics (ALDX) Amortizatization of Intangibles (2013 - 2025)
Aldeyra Therapeutics (ALDX) posted Amortizatization of Intangibles of -$887215.0 for Q4 2025, down 432.84% on a QoQ basis from $266560.0 in Q3 2025, and down 157.7% year-over-year from $1.5 million in Q4 2024.
Aldeyra Therapeutics (ALDX) Amortizatization of Intangibles (2013 - 2025) Analysis & Trends
Aldeyra Therapeutics' Amortizatization of Intangibles history runs 13 years deep, the most recent figure standing at -$887215.0 for Q4 2025.
- Quarterly Amortizatization of Intangibles fell 157.7% year-over-year to -$887215.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $151103.0 (down 91.01% YoY) and the FY2025 annual result came in at $218260.0, down 86.94% from the prior year.
- Amortizatization of Intangibles was -$887215.0 for Q4 2025 at Aldeyra Therapeutics, down from $266560.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.5 million in Q4 2024 and bottomed at -$887215.0 in Q4 2025.
- A 5-year average of $165780.9 and a median of $82799.5 in 2021 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles sank 308.89% — and 2024, when it jumped 536.8%.
- Aldeyra Therapeutics' Amortizatization of Intangibles stood at $82799.0 in 2021, then retreated by 0.06% to $82753.0 in 2022, then surged by 310.44% to $339651.0 in 2023, then jumped by 352.69% to $1.5 million in 2024, then plunged by 157.7% to -$887215.0 in 2025.
- Business Quant data shows ALDX's Amortizatization of Intangibles at -$887215.0 in Q4 2025, $266560.0 in Q3 2025, and $771758.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Aldeyra Therapeutics | 95.00 Mn | 95.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -887,215.00 |
| Dec 31, 2025 | -887,215.00 |
| Sep 30, 2025 | 266,560.00 |
| Sep 30, 2025 | 266,560.00 |
| Jun 30, 2025 | 771,758.00 |
| Jun 30, 2025 | 771,758.00 |
| Mar 31, 2025 | 67,157.00 |
| Mar 31, 2025 | 67,157.00 |
| Dec 31, 2024 | 1.54 Mn |
| Dec 31, 2024 | 1.54 Mn |
| Sep 30, 2024 | -563,708.00 |
| Sep 30, 2024 | -563,708.00 |
| Jun 30, 2024 | 638,967.00 |
| Jun 30, 2024 | 638,967.00 |
| Mar 31, 2024 | 58,152.00 |
| Mar 31, 2024 | 58,152.00 |
| Dec 31, 2023 | 339,651.00 |
| Dec 31, 2023 | 339,651.00 |
| Sep 30, 2023 | -172,959.00 |
| Sep 30, 2023 | -172,959.00 |